Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1239 - Clinicopathologic features and long-term follow-up of metastatic gastrointestinal stromal tumor (GIST) patients (pts) with durable response (≥ 5 years) to frontline imatinib (IM): a case-control study from GEIS


11 Sep 2017


Poster display session


Cytotoxic Therapy;  GIST


Cesar Serrano


Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387


C. Serrano1, A. Lopez Pousa2, I. Pajares3, C. Valverde Morales1, J. Duran4, J. Rubió-Casadevall5, M.J. Safont6, V. Martinez7, R. Díaz Beveridge8, A. Estival9, D. Vicente Baz10, A. Sebio Garcia2, N. Hindi11, S. Landolfi12, D. Olivares1, A. Garcia-Valverde1, P. Ledesma13, J. Arribas14, J. Carles Galceran1, J. Martin Broto11

Author affiliations

  • 1 Medical Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 2 Medical Oncology, Hospital de la Santa Creu i Sant Pau, 8026 - Barcelona/ES
  • 3 Medical Oncology, Hospital Miguel Servet, 50009 - Zaragoza/ES
  • 4 Medical Oncology, Hospital Universitario Son Espases, 07010 - Palma/ES
  • 5 Medical Oncology, Hospital Josep Trueta, Gerona/ES
  • 6 Medical Oncology, Hospital General de Valencia, Valencia/ES
  • 7 Medical Oncology, Hospital La Paz, Madrid/ES
  • 8 Medical Oncology, Hospital Universitari i Politècnic La Fe, 46026 - Valencia/ES
  • 9 Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 8916 - Badalona/ES
  • 10 Medical Oncology, Hospital Universitario Virgen Macarena, 41003 - Sevilla/ES
  • 11 Medical Oncology, Hospital Universitario Virgen del Rocio, 41013 - Sevilla/ES
  • 12 Surgical Pathology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 13 Sofpromed Investigación Clínica, GEIS, Palma/ES
  • 14 Preclinical Program, Vall d'Hebron University Hospital, 8035 - Barcelona/ES


Abstract 1239


IM achieves disease control in most metastatic GIST pts, typically about 18 months. Interestingly, ∼15% GIST pts remain on IM beyond 5 years of continuous treatment. To date, clinicopathologic features predictive of long-term benefit to IM remain largely unknown.


We analyzed clinical, pathological and molecular characteristics, and long-term outcomes in metastatic GIST pts treated with continuous daily dosing of frontline IM in a cohort of pts benefiting ≥ 5 years, compared with a control group obtained from a national GEIS database.


We found 41 IM long-term responders (IM-LTR) and 71 control cases (CC) with a median time on IM of 90.6 and 18.2 months, respectively. Compared to CC, IM-LTR were younger (59 vs 64 years, p = 0.040), fitter at diagnosis (performance status (PS) 0-1: 100% vs 82.2%, p 


Clinical and inherently biological tumor characteristics define a subset of GIST pts with increased likelihood to achieve durable benefit from IM. Molecular studies are needed to better identify these pts at treatment initiation.

Clinical trial identification

Legal entity responsible for the study

Spanish Group of Sarcoma Research (GEIS)


Spanish Group of Sarcoma Research (GEIS)


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.